⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SXTP News
60 Degrees Pharmaceuticals, Inc. Common Stock
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
globenewswire.com
SXTP
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
globenewswire.com
SXTPW
SXTP
Form 8-K
sec.gov
SXTPW
SXTP
Form 8-K
sec.gov
SXTP
SXTPW
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
globenewswire.com
SXTP
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
globenewswire.com
SXTP
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
globenewswire.com
SXTP
Form 8-K
sec.gov
SXTPW
SXTP
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
globenewswire.com
SXTP
Form 8-K
sec.gov
SXTPW
SXTP
CERO
SCYX